Prolonged apnea after remifentanil.
A young, healthy adult man exhibited naloxone-reversible, prolonged apnea after a 4-hour infusion of remifentanil, which was used as the opioid component of a general endotracheal anesthetic. Clinical experience and pharmacokinetic simulations indicate that the apnea was clearly atypical.
Nelson
Reed Y
RY
Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, WI, USA.
Bretz
Brad
B
Egan
Talmage D
TD
D000328:Adult; D000701:Analgesics, Opioid / Q000009:adverse effects* / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics; D000768:Anesthesia, General; D001049:Apnea / Q000139:chemically induced / Q000188:drug therapy*; D003399:Craniotomy; D006801:Humans; D008297:Male; D009270:Naloxone / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D010880:Piperidines / Q000009:adverse effects* / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics; D011183:Postoperative Complications / Q000139:chemically induced / Q000188:drug therapy*; D000077208:Remifentanil; D013997:Time Factors
D000701:Analgesics, Opioid; D009292:Narcotic Antagonists; D010880:Piperidines; D009270:Naloxone; D000077208:Remifentanil